在阿尔茨海默病中,通过活动来抑制加速认知衰退
1Mary S. Easton Center for Alzheimer's Research and Care, Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Journal of Alzheimer's disease : JAD
|July 31, 2023
概括
抗发作药物 (ASD) 在大多数阿尔茨海默病 (AD) 和 (epAD) 患者中有效控制发作. 经过治疗的epAD患者表现出类似于没有的AD患者的认知衰退,这表明结果有所改善.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 活动是一种已知的并发症,可恶化阿尔茨海默病 (AD) 病理和进展.
- 抗发作药物 (ASD) 对阿尔茨海默病和 (epAD) 患者的治疗益处仍未得到充分研究.
研究的目的:
- 评估ASDs在控制预发性AD和 (epAD) 患者的发作的疗效.
- 评估ASD治疗对epAD患者认知衰退的影响,与没有的AD患者相比.
主要方法:
- 对被诊断患有前发性AD和 (epAD) 的患者的回顾性分析.
- 以低剂量ASD单疗法治疗epAD患者的控制率和认知进展的评估.
- 治疗epAD患者和没有的AD患者的对照组之间的认知衰退的比较.
主要成果:
- 绝大多数epAD患者通过ASD单一治疗实现了控制.
- 经过治疗的epAD患者表现出与没有的AD患者相比的认知衰退率.
- 在这个患者队列中,低剂量ASD单疗法是有效的,并且耐受良好.
结论:
- 抗发作药物治疗在患有前发性阿尔茨海默病的患者中有效治疗.
- 控制ASD的活动可能会减缓认知衰退,改善epAD患者的结果.
- 需要进一步的研究来证实这些发现,并优化治疗策略.
相关概念视频
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
Cognitive Development During Adulthood
158
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
158
Role of Neurotransmitters in Memory
630
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
630
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139


